Nippon Pharmaceuticals to Issue IPO, Appoints Nabil Investment Banking as Issue Manager

Nippon Pharmaceuticals Limited is preparing to issue its initial public offering (IPO) to the general public after obtaining the required approvals from the regulatory authorities.

The company has appointed Nabil Investment Banking Limited as the issue and sales manager for the proposed IPO. An agreement was signed by Nippon Pharmaceuticals Managing Director Mantu Ghimire and Nabil Investment Banking CEO Manish Narayan Joshi.

Nippon Pharmaceuticals, registered in 2006 and established as an industry in 2017, started commercial production and marketing in 2022. The company manufactures medicines including tablets, capsules, liquid medicines, ointments, creams, gels, ORS, dry syrups and penicillin in line with international quality standards.

The company currently markets more than 60 products across various therapeutic segments.